• Publications
  • Influence
Long-Term Results of a Prospective Surgical Trial Comparing 2 cm vs. 4 cm Excision Margins for 740 Patients With 1–4 mm Melanomas
Background:The Intergroup Melanoma Surgical Trial began in 1983 to examine the optimal surgical margins of excision for primary melanomas of intermediate thickness (i.e., 1–4 mm). There is now aExpand
  • 192
  • 8
Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)
BACKGROUND: Ten- to 15-year survival results were analyzed from a prospective multi-institutional randomized surgical trial that involved 740 stages I and II melanoma patients with intermediateExpand
  • 391
  • 2
  • Open Access
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas.
Background:The Intergroup Melanoma Surgical Trial began in 1983 to examine the optimal surgical margins of excision for primary melanomas of intermediate thickness (i.e., 1–4 mm). There is now aExpand
  • 191
  • 2
Surgical Resection Is Necessary To Maximize Tumor Control in Function-Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV)
Background:The role of surgery in aggressive chemoradiation protocols for advanced head and neck cancer has been questioned because of the quoted high clinical response rates in manyExpand
  • 53
  • 2
Cetuximab, Paclitaxel, Carboplatin, and Radiation For Head and Neck Cancer: A Toxicity Analysis
Objective:To determine the feasibility and toxicity of the addition of cetuximab to paclitaxel, carboplatin, and concurrent radiation for patients with head and neck cancer. Materials andExpand
  • 20
  • 1
Cetuximab, Paclitaxel, Carboplatin, and Radiation for Head and Neck Cancer: A Survival Analysis of a Brown University Oncology Group Phase II Study
Objectives:To assess the effect on progression-free and overall survival from the addition of cetuximab to paclitaxel-based chemoradiation for patients with squamous cell head and neck cancer fromExpand
  • 4
Isolated chemotherapeutic perfusion as neoadjuvant therapy for advanced/unresectable pelvic malignancy
2555 Background: Isolated pelvic perfusion (IPP) provides higher tissue drug levels than high-dose systemic therapy and may enhance resectability and survival in patients failing chemo radiation ±Expand
Aggressive regional therapy vs conventional treatment of patients with unresected liver metastases from colorectal cancer: A multivariate analysis focused on overall survival
3675 Background: The prognosis of unresected colorectal (CRC) liver metastases is poor. Most patients receive systemic chemotherapy or supportive care only. There is suggested survival benefit withExpand